Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SCN1A | P35498 | 1/20 | 0.37 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.37 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4710809 | 0.86 | NPSR1 (0.47) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4709960 | 0.86 | NPSR1 (0.43) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4713269 | 0.84 | NPSR1 (0.42) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4711412 | 0.84 | NPSR1 (0.42) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4713572 | 0.82 | NPSR1 (0.43) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4709422 | 0.82 | NPSR1 (0.43) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4789782 | 0.81 | NPSR1 (0.40) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4709385 | 0.80 | NPSR1 (0.42) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL4711670 | 0.80 | NPSR1 (0.42) | NPSR1LMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL16190055 | 0.79 | NPSR1 (0.41) | NPSR1LMNASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1398309-B1 | NOVEL ADAMANTANE DERIVATIVE | IDEMITSU KOSAN CO (JP) | 2008-02-20 | — | — | EP | disclosed |
| US-6833388-B2 | 1,3-adamantanedicarboxylic acid-bis(2'-alkyl-2'-adamantyl)-esters; photoresist additive; resin heat resistance improver; pharmaceutical and agrochemical intermediates | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20040157923-A1 | Novel adamantane derivative | IDEMITSU KOSAN CO. LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
| EP-1398309-A1 | NOVEL ADAMANTANE DERIVATIVE | IDEMITSU PETROCHEMICAL CO., LTD. (JP) | 2004-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157923-A1 | Novel adamantane derivative | TAS1R1, TAS2R1, ADORA1 | NPSR1 131/4885LMNA 4176/4885SMN1; SMN2 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.